Published online 23 November 2008
Haematologica, Vol 94, Issue 1, 148-150 doi:10.3324/haematol.13533
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Wrench et al. - Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wrench, D.
Right arrow Articles by Fitzgibbon, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wrench, D.
Right arrow Articles by Fitzgibbon, J.

Malignant Lymphomas

Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma

David Wrench1, Rachel Waters2, Emanuela Carlotti1, Sameena Iqbal1, Janet Matthews3, Marie Calaminici4, John Gribben1, T. Andrew Lister1, Jude Fitzgibbon1

1 Centre for Medical Oncology, Barts and the London School of Medicine, London
2 Centre for Statistics in Medicine, University of Oxford, Oxford
3 Data Management Unit, Medical Oncology Department, Barts and the London NHS Trust, London
4 Histopathology Department, Barts and the London NHS Trust, London, UK

Correspondence: David Wrench, Centre for Medical Oncology, Barts and the London School of Medicine, Charterhouse Square London, EC1M 6BQ, UK. Phone: international +44.20.78826052. Fax: international +44.20.78826004. E-mail:djwrench{at}doctors.org.uk

Key words: follicular, lymphoma, MDM2, TP53, SNPs.

Tumor protein 53 (TP53) is critical to cell cycle control and is the most common mutational target in germinal center lymphomas. However, these mutations occur infrequently at diagnosis (<10%) in follicular lymphoma (FL), and are more commonly associated with disease progression or transformation to more aggressive histology.1–4 Inactivation of TP53 may also occur by upregulation of the human homolog of the Murine Double Minute 2 protein (MDM2), which targets TP53 for degradation by the proteasome and is frequently amplified in FL and other malignancies; indeed Mdm2 haplo-insufficiency in mice leads to enhanced TP53 function with delayed onset of lymphoma.5 While many studies have examined the genomic events targeting these loci, less is known as to the functional role of polymorphic variants at the MDM2 or TP53 loci. The single nucleotide polymorphisms (SNPs), MDM2 SNP 309 and TP53 Arg72Pro, have at least in some studies an additive effect on cancer susceptibility with MDM2 SNP 309 also predicting advanced disease at diagnosis.6 Consequently, we investigated the impact of MDM2 SNP 309 and TP53 Arg72Pro on the clinical outcome of FL. MDM2 SNP 309 characterizes a T>G substitution at nucleotide 309 of intron one and leads to higher MDM2 mRNA and protein expression with lower apoptotic response. Significantly, homozygosity for the G allele correlates with earlier onset of de novo diffuse large B-cell lymphoma (DLBCL) in females7 Its role in CLL is less clear as two recent studies provide contrasting results.8,9 TP53 Arg72Pro is a non-synonymous SNP involving G>C substitution at nucleotide 466 of exon 4 in TP53 which creates a TP53 protein with reduced potential to induce apoptosis or suppress cell transformation.10 These SNPs are also associated with poor prognosis or increased cancer risk in certain solid malignancies.11,12

We investigated the relationship of the allelic combinations for both SNPs with the following clinical variables in cases of FL: age, gender, stage at diagnosis, response to first line therapy, best response to therapy, progression-free survival, relapse-free survival, overall survival and time to transformation (Details of each variable are available in the Online Supplementary Table S1). A real-time polymerase chain reaction Allelic Discrimination multiplexed endpoint assay protocol using the ABI PRISMTM 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA) was used to determine the SNP alleles present in DNA of 226 patient samples from bone marrow (n=207), peripheral blood (n=14) or lymph nodes (n=5). (Oligonucleotide sequences used are available on request.) Samples were obtained from the tissue archive at St Bartholomew’s Hospital under Institutional Ethical Approval obtained from the Local Ethics Committee. Reactions were performed in duplicate including homozygous and heterozygous controls for each SNP genotype and a no DNA template control. Positive controls were confirmed by direct sequencing.

In this patient cohort, allelic frequencies were similar to previously published results at 44%, 43%, 13% for MDM2 SNP 309 TT, TG, GG and at 46%, 46%, 8% for TP53 Arg72Pro GG, GC, CC respectively (Online Supplementary Table S2) and both polymorphisms satisfied the Hardy-Weinberg equilibrium. Median age at diagnosis was 46 years, which is younger than that previously described for FL, and reflects our status as a tertiary referral center for patients with FL. There was no difference in the median age at diagnosis for each of the 3 allelic combinations of MDM2 SNP 309 (both for the whole study population and for gender in contrast to findings in DLBCL7) and of TP53 Arg53Pro (Online Supplementary Table S2).

Relationships between SNP alleles and clinical parameters were studied using {chi}2 test for stage and gender, analysis of variance (ANOVA) for age and Kruskal-Wallis test for responses to therapy. The 3 allelic combinations for each SNP were informally assessed as well as formally assessing two groups of patient samples consisting of those homozygous for the common allele or those with at least one rare allele, enabling any dominant effects of the MDM2 SNP 309 G or TP53 Arg72Pro C alleles, as described in other malignancies, to be assessed in FL. As MDM2 SNP 309 can lead to earlier onset or more advanced disease6 and TP53 negatively regulates MDM2 expression, we assessed MDM2 SNP 309 alleles in isolation or in combination with TP53 Arg72Pro alleles against these clinical parameters; there was no evidence of any association (illustrated in Table 1 for gender, stage and responses to therapy; p≥0.13). Kaplan-Meier plots and log rank test statistics demonstrated no evidence for associa-ion oft MDM2 SNP 309 or TP53 Arg72Pro allelic variants alone, or in combination, with overall survival (Figure 1A), progression free survival, relapse free survival or time to transformation (Figure 1B) (p≥0.17).


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		Table 1. Assessment of MDM2 SNP 309 and TP53 Arg72Pro against clinical parameters


Figure 10940148
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Kaplan-Meier plots and log rank test statistics for overall survival (A) and time to transformation (B) by MDM2 SNP 309 and TP53 Arg72Pro alleles. Illustrated are results for four groups of allelic combinations of the two SNPs. The four groups Neither rare, Rare TP53, Rare MDM2 and Both rare are defined in Table 1. In addition, no associations were seen between the 3 allelic combinations for each SNP and the survival parameters, nor were associations seen on informal analyses of all possible allelic combinations between the two SNPs (data not shown).

Consequently, whilst genomic lesions targeting the MDM2-TP53 axis are an important feature of FL, MDM2 SNP 309 and TP53 Arg72Pro do not predict clinical outcome. In contrast to other malignancies these polymorphisms are not significant in FL.


arrow
Footnotes
 
Funding: this work was supported by Cancer Research UK, the Cancer Committee of Barts and the London NHS Trust and the Research Advisory Board of Barts and the London Medical School


arrow
References
TOP
 References
 
  1. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004.[Abstract/Free Full Text]
  2. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993;82:2289-95.[Abstract/Free Full Text]
  3. Symmans WF, Katz RL, Ordonez NG, Dalton H, Romaguera JE, Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol 1995;39:673-82.[Medline]
  4. Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005;19:1459-65.[CrossRef][Web of Science][Medline]
  5. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. Embo J 2003;22:1442-50.[CrossRef][Web of Science][Medline]
  6. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.[Abstract/Free Full Text]
  7. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.[Abstract/Free Full Text]
  8. Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008;26:2252-7.[Abstract/Free Full Text]
  9. Zenz T, Häbe S, Benner A, Kienle D, Döhner H, Stilgenbauer S. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 2008;93:1111-3.[Free Full Text]
  10. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.[Abstract/Free Full Text]
  11. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-40.[Abstract/Free Full Text]
  12. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-7.[CrossRef][Web of Science][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Wrench et al. - Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wrench, D.
Right arrow Articles by Fitzgibbon, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wrench, D.
Right arrow Articles by Fitzgibbon, J.